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The Amyloid-Fibril-Forming Properties of the Amphibian
Antimicrobial Peptide Uperin 3.5
Antonio N. Calabrese,[a] Yanqin Liu,[a, e] Tianfang Wang,[b, e] Ian F. Musgrave,[a] Tara L. Pukala,[a]
Rico F. Tabor,[c] Lisandra L. Martin,*[c] John A. Carver,*[d] and John H. Bowie[a]
Introduction
The majority of animals and plants have innate immune sys-
tems that comprise antimicrobial peptides (AMPs) as a vital
component.[1] Often, upon receipt of a suitable stress stimulus,
a range of AMPs with a spectrum of activities is secreted to
ensure a fast, effective response against any invading mi-
crobe(s).[2] During the last 25 years, some 200 host-defence
peptides have been isolated from the skin secretions of Aus-
tralian frogs and toads. Many of these peptides are AMPs and/
or have one or more neuropeptide-type activities.[3] This
potent chemical arsenal ensures that the animal is effectively
protected from the plethora of microbes that are rife in the
hostile environment in which they live. The prevalence of
AMPs in nature demonstrates their effectiveness as defence
compounds, and their high activity and selectivity for microbes
makes them an attractive starting point for the development
of new peptide-based antimicrobials.[4]
AMPs often cause the death of microorganisms by interact-
ing with the lipid bilayer and then causing membrane disrup-
tion in a specific, but not receptor-mediated, process.[1a,2] Sev-
eral models have been proposed to describe this process of
membrane permeabilisation.[4d,5] However, the finding that sev-
eral AMPs have the ability to form b-sheet-rich amyloid fibril
structures has led to the postulation that two seemingly unre-
lated classes of polypeptides, AMPs and fibril-forming (amyloi-
dogenic) peptides, share common mechanisms of cytotoxicity
through membrane disruption.[6]
The ability to form amyloid fibrils is proposed to be a generic
property of all polypeptide sequences when they are subjected
to the appropriate environmental and physicochemical stress-
es, with all amyloid fibrils sharing similar structural characteris-
tics, irrespective of the protein from which they are derived.[7]
A number of human diseases have the hallmark histological
feature of extra- or intracellular amyloid deposits, including
neurodegenerative diseases such as Alzheimer’s and Parkin-
son’s diseases, which are characterised by amyloid deposits of
the amyloid b peptide (Ab) and a-synuclein, respectively. Sev-
eral mechanisms to rationalise the cytotoxicity of amyloido-
genic species have been proposed, with the most toxic species
postulated to be the oligomeric, pre-fibrillar aggregates,[8]
which might function by forming pores in cellular membranes
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The amphibian skin is a vast resource for bioactive peptides,
which form the basis of the animals’ innate immune system.
Key components of the secretions of the cutaneous glands are
antimicrobial peptides (AMPs), which exert their cytotoxic ef-
fects often as a result of membrane disruption. It is becoming
increasingly evident that there is a link between the mecha-
nism of action of AMPs and amyloidogenic peptides and pro-
teins. In this work, we demonstrate that the broad-spectrum
amphibian AMP uperin 3.5, which has a random-coil structure
in solution but adopts an a-helical structure in membrane-like
environments, forms amyloid fibrils rapidly in solution at neu-
tral pH. These fibrils are cytotoxic to model neuronal cells in
a similar fashion to those formed by the proteins implicated in
neurodegenerative diseases. The addition of small quantities of
2,2,2-trifluoroethanol accelerates fibril formation by uperin 3.5,
and is correlated with a structural stabilisation induced by this
co-solvent. Uperin 3.5 fibril formation and the associated cellu-
lar toxicity are inhibited by the polyphenol ()-epigallocate-
chin-3-gallate (EGCG). Furthermore, EGCG rapidly dissociates
fully formed uperin 3.5 fibrils. Ion mobility–mass spectrometry
reveals that uperin 3.5 adopts various oligomeric states in solu-
tion. Combined, these observations imply that the mechanism
of membrane permeability by uperin 3.5 is related to its fibril-
forming properties.
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in a similar way to AMPs.[9] The fibrils themselves are consid-
ered less cytotoxic or could in some cases be an inert, protec-
tive accumulation of the toxic species. However, in some cases,
fibril cytotoxicity has been observed,[10] and fibril assembly on
membranes can lead to cell death.[11] The largely unexplained
cytotoxic mechanism of amyloid disease makes this field an
active area of research, with numerous studies attempting to
inhibit amyloid formation by use of small-molecule or peptide
inhibitors.[12]
AMPs and amyloidogenic proteins share many structural and
functional characteristics. These include their high affinities for
negatively charged membranes, and a structural conversion
from random-coil to a-helical secondary structure upon inter-
acting with the membrane.[8c,13] In addition to some mem-
brane-bound AMPs undergoing conversion to amyloid-like fi-
brils,[6] the amphibian AMP dermaseptin forms amyloid fibrils
in solution.[14] The investigation of this novel relationship be-
tween AMPs and amyloid formation by disease-related pro-
teins will potentially enable significant advances in under-
standing both amyloid diseases and the mechanism of action
of AMPs.[15]
In this paper, we demonstrate that the 17-residue peptide
uperin 3.5 (GVGDLIRKAVSVIKNIV-NH2), a broad-spectrum AMP
isolated from the skin secretions of the Australian toadlet Uper-
oleia mjobergii,[16] rapidly forms amyloid-like fibrils. By combin-
ing a variety of biophysical techniques, including thioflavin T
(ThT) fluorescence, transmission electron microscopy (TEM)
and ion mobility–mass spectrometry (IM-MS), insights have
been gained into fibril formation by this peptide. We demon-
strate that partial stabilisation of the a-helical secondary struc-
ture promotes fibril formation, and that the fibrils themselves
share cytotoxic properties with amyloid species from the pep-
tides and proteins implicated in neurodegenerative diseases.
Fibril formation and its associated cytotoxic effects can be in-
hibited in the presence of the polyphenol ()-epigallocate-
chin-3-gallate (EGCG). Potentially, amyloid formation plays a piv-
otal role in the AMP activity of uperin 3.5.
Results
Uperin 3.5 self assembly
The ability of several AMPs from Australian amphibians to form
amyloid fibrils was assessed in vitro. From this initial screen, it
was noticed that uperin 3.5 self assembles to form amyloid fi-
brils in buffered solutions at physiological pH. The fibril forma-
tion process was investigated by using several methods. Firstly,
an in situ ThT fluorescence assay monitored the kinetics of
fibril formation by uperin 3.5 (Figure 1A). An increase in fluo-
rescence was observed as a function of time; this is consistent
with the formation of b-sheet-rich aggregates and a conversion
from monomeric peptide to amyloid fibrils. Little to no lag
phase was observed, and the elongation phase was complete
within approximately 5 h. Furthermore, decreasing the concen-
tration did not result in distinguishable differences in lag
times, however, a reduction in fibril yield was observed (Fig-
ure S1 in the Supporting Information).
The morphology of the resultant fibrils was analysed by TEM
and AFM (Figure 1A, inset). The fibrillar species produced are
approximately 20 nm high and 400 nm in length, with charac-
teristic coiled-coil ultrastructure. The secondary structure con-
tent of the resultant fibrils, when compared with the native
peptide, was examined by using far-UV CD spectroscopy (Fig-
ure 1B). During incubation of uperin 3.5, a transition occurred
from a random-coil structure (with a CD spectrum displaying
a characteristic ellipticity minimum at approximately 195 nm)
to a structural ensemble comprising significant b-sheet confor-
mation with a broad negative ellipticity maximum at approxi-
mately 218 nm, characteristic of amyloid fibrils. Some a-helical
structure is also possibly present with broad minima at approx-
imately 208 and 222 nm, indicative of the pathway to the final
b-sheet-rich structure.
Modulation of uperin 3.5 secondary structure and self-as-
sembly with 2,2,2-trifluoroethanol
TFE destabilises hydrophobic interactions within polypeptide
chains and stabilises local hydrogen bonds between proximal
residues in a polypeptide. Consequently, as a cosolvent it is ca-
pable of stabilising secondary structure where it has the pro-
pensity to form.[17] In buffered aqueous solution, uperin 3.5 ex-
hibits a far-UV CD spectrum characteristic of a random-coil
structure, however, addition of TFE (0–50%, v/v) to native
Figure 1. Amyloid fibril formation by uperin 3.5. A) In situ ThT fluorescence
assay of fibril formation by uperin 3.5 at 37 8C in PBS. Representative data
from three independent experiments performed in triplicate are shown. The
insets show representative TEM and AFM images of the fibrillar species ob-
served after 24 h (scale bars: 1 mm). B) Far-UV CD spectra of a freshly pre-
pared 3 mm solution of uperin 3.5 (c) and a solution incubated at 37 8C
for 5 h (a).
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uperin 3.5 showed that a-helical structure is induced in a con-
centration-dependent manner, as evidenced by the far-UV CD
spectra, which show characteristic negative ellipticity maxima
at approximately 210 and 220 nm (Figure 2A). Addition of TFE
to the in-situ ThT fluorescence assay demonstrates that the
presence of 10% (v/v) TFE enhances aggregation significantly,
20% (v/v) TFE only moderately enhances aggregation, and the
addition of 50% (v/v) TFE &&eliminates fibril formation (Fig-
ure 2B); this was confirmed by TEM imaging (data not shown)
OK?&&. Fibril morphology is not affected significantly by the
presence of TFE, as indicated by TEM imaging (Figure 2C and
D).
Ion mobility–mass spectrometry analysis of prefilbrillar olig-
omers of uperin 3.5
Mass spectrometry is emerging as an important technique for
studying early-stage peptide/protein oligomerisation, especial-
ly due to its unique ability to detect the lowly populated tran-
sient intermediate states occupied on the way to amyloid fi-
brils.[18] In order to study the self-assembly of uperin 3.5 by
nanoelectrospray-ion mobility–MS (IM-MS), it was necessary to
determine if the peptide was capable of forming amyloid fibrils
in solutions of MS-compatible buffers. Thus, an in-situ ThT fluo-
rescence assay was undertaken for a 100 mm solution of
uperin 3.5 in 50 mm ammonium acetate (pH 6.9). The kinetics
of fibril formation were not significantly different from those in
phosphate buffer, and the morphology of the fibrils was also
similar, as determined by TEM (data not shown).
The early-stage prefibrillar oligomeric states were studied by
IM-MS by using freshly prepared peptide solutions, as the rela-
tive abundance of oligomeric species observed by IM-MS de-
creases as a function of aggregation time, most likely due to
the higher-order oligomers being incorporated into fibrils.[19]
Figure 3A shows the mass spectrum of uperin 3.5, with the
oligomers (and their charge states) indicated. Oligomeric states
up to a hexamer were observed in the IM-MS spectrum. The
observed oligomers all adopted only one or two charge states
Figure 2. Effect of 2,2,2-trifluoroethanol on the conformation and aggrega-
tion of uperin 3.5. A) Far-UV CD spectrum of uperin 3.5 in PBS (c), and in
the presence of 10 (c), 20 (c) and 50% (c) TFE. B) In situ ThT fluo-
rescence assay showing the kinetics of fibril formation by uperin 3.5 (c),
and in the presence of 10 (c), 20 (c) and 50% (c) TFE. Representa-
tive data from three independent experiments performed in triplicate are
shown. TEM images of the fibrillar species produced by uperin 3.5 after incu-
bation at 37 8C for 24 h in the presence of C) 10 and D) 20% TFE. Scale bars:
200 nm.
Figure 3. IM-MS analysis of uperin 3.5 oligomerisation. A) Mass spectrum of
100 mm uperin 3.5 in 50 mm NH4OAc (pH 6.9). The peaks are labelled accord-
ing to the number of peptides per oligomer, with their charge state indicat-
ed as a superscript. B) The arrival time distribution of isobaric ions with m/z
1781. The peaks show two oligomeric states that can be identified by their
isotopic distributions. The 22+ species has a longer drift time than the 33+
species. C) The isotopic distributions for the 22+ (top, arrival time of
23.25 ms) and 33+ (bottom, arrival time of 15.50 ms) oligomers. D) Measured
uperin 3.5 CCSs plotted as a function of the number of subunits in the oligo-
mer. The blue dotted line displays estimated CCSs assuming an isotropic as-
sembly process (here the CCS of the monomer is scaled by n2/3, where n is
the number of subunits in the oligomer),[20] and the green line corresponds
to the expected CCSs for globular proteins, based on the average density of
a protein (0.44 Da13).[21] The dotted line shows a linear regression analysis
of the experimental data points, r2=0.99.
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upon ionisation; this indicates that they are of relatively com-
pact, well-defined structures.
Importantly, IM-MS allows species of the same m/z, but dif-
ferent mass and charge to be separated; this is illustrated in
Figure 3B, which shows the arrival time distribution (ATD) of
ions with m/z 1781. Two different species are present, and sep-
arating them allows their respective isotopic distributions to
be observed (Figure 3C). Generally, more highly charged oligo-
mers have higher mobility, and therefore a shorter drift time.
This is observed for uperin 3.5, with the trimer (+3 charge
state) having a shorter drift time than the dimer (+2 charge
state; Figure 3B, C).
IM-MS also permits the separation of ions with identical
mass and m/z, but different conformations. Both doubly and
triply charged monomer charge states were observed, with
each charge state having both an expanded and compact con-
formation for the same mass species (Table S1). ATDs were ex-
tracted from the spectra for the oligomeric species observed.
The drift times were converted to rotationally averaged colli-
sion cross-sections (CCS) by using a calibration protocol[22] and
compared with those estimated for several theoretical models,
such as those assuming an isotropic growth,[20] a model assum-
ing a globular size (based on an average protein density of
0.44 Da13),[21] and an linear growth model[20] (Figure 3D and
Table S1). As seen in Figure 3D, the CCS measurements indi-
cate that oligomeric growth occurs in a directional fashion;
this is consistent with a linear growth model.
Influence of uperin 3.5 on the viability of PC12 cells mea-
sured by MTT reduction
It is well known that the amyloidogenic forms of proteins dis-
play enhanced cytotoxicity relative to the unaggregated spe-
cies.[10a–c] To assess this effect, the influence of native and fibril-
lar uperin 3.5 on the viability of cultured pheochromocytoma-
12 (PC12) cells, a neuronal cell model,[23] was determined by
using the methylthiazolyldiphenyl-tetrazolium bromide (MTT)
assay.[23]
Treatment of cells with preincubated uperin 3.5, which had
formed amyloid-like fibrils (as evidenced by ThT fluorescence
and TEM imaging), caused a dose-dependent decrease in cell
viability (Figure 4). In the main, this effect was not observed
with native (un-incubated) peptide, as measured by the MTT
assay. The native peptide forms caused a decrease in cell via-
bility at high concentration (50 mm), most likely due to forma-
tion of aggregates in the culture medium.[23]
()-Epigallocatechin-3-gallate inhibits amyloid formation by
uperin 3.5 and disassembles preformed fibrils
The polyphenol ()-epigallocatechin-3-gallate (EGCG) and
other related molecules have been the subject of much re-
search due to their ability to inhibit amyloid formation by a va-
riety of disease-related proteins.[24] The anti-aggregation effica-
cy of EGCG towards uperin 3.5 was monitored in an in situ ThT
fluorescence assay. Uperin 3.5 (100 mm) was incubated at 37 8C
in the presence of a fourfold molar excess of EGCG; this result-
ed in the complete mitigation of any time-dependent increase
in ThT fluorescence (Figure 5A), thus implying that EGCG pre-
vented fibril formation by uperin 3.5. Furthermore, addition of
EGCG after the elongation phase resulted in a decrease in ThT
fluorescence, indicative of fibril disassembly (Figure 5A). In ad-
dition, the change in aggregate morphology induced by EGCG
was monitored by using TEM. The images show a redirection
of fibril formation towards amorphous aggregation (Figure 5B–
D).
EGCG also prevented the formation of the higher-order olig-
omers observed by IM-MS (Figure 3), whereby multiple copies
of EGCG were observed to be bound to monomeric uperin 3.5
(Figure S3). This is typical of the inhibition of fibril formation
attributed to nonspecific binding to the monomeric peptide,
rather than EGCG binding at a specific site.
Finally, to assess the cytoprotective activity of EGCG, PC12
cells were treated with uperin 3.5 preincubated at 37 8C for
24 h with and without EGCG. Following incubation of the
treated cells for 48 h, cell viability was assessed by MTT reduc-
tion. Treatment with EGCG alone did not result in a change in
cell viability. Significant protection from the amyloid-associated
decrease in cell viability, as measured by the MTT reduction,
was observed when uperin 3.5 was coincubated with EGCG
(Figure 5E).
Discussion
Amyloid fibril formation by uperin 3.5
In this work we have comprehensively investigated the amyloi-
dogenicity of the amphibian AMP uperin 3.5, which forms amy-
loid fibrils rapidly under physiological conditions (Figure 1),
a process that might be involved in its biological function.
Solution conditions are well known to affect &&the fibril-
formation kinetics of OK?&& peptides and proteins. For ex-
ample, the presence of co-solvents, high temperatures and ex-
treme pH, alter the kinetics and extent of aggregation.[25] Tri-
Figure 4. Concentration-dependent influence on cell viability of native and
fibrillar uperin 3.5 as measured by MTT reduction. Uperin 3.5 was dissolved
in PBS, then either frozen in its native form or incubated for 24 h at 37 8C to
induce fibril formation. Native (&) and fibrillar (*) forms of uperin 3.5 were
then added to the cell culture medium (RPMI 1640) of the PC12 cells, and
they were incubated for 48 h. Cell viability was assessed by using the MTT
assay. Values are presented as percentage of cell survival compared with
a controlSEM of three independent experiments, each with six replicates.
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fluoroethanol is a well-known organic cosolvent that has the
ability to induce secondary structure, in particular helical con-
formation, where it has the propensity to form.[17b] Additionally,
TFE mimics a membrane environment.[26] A variety of proteins
and peptides form fibrils in the presence of TFE.[25b,27]
It is apparent that adding TFE to uperin 3.5-containing solu-
tions triggers the conversion from a random-coil conformation
to an a-helical structure, as evidenced by the far-UV CD spec-
tra in Figure 2A, which show overall enhanced helicity in
uperin 3.5 when increasing amounts of TFE are added. Impor-
tantly, the far-UV CD spectra demonstrate that in 10 and 20%
(v/v) TFE, a small degree of a-helical secondary structure is in-
duced; this increases upon addition of 50% (v/v) TFE. Despite
this, amyloid fibrils are still formed in both 10 and 20% aque-
ous TFE solutions, but this process is inhibited in 50% aqueous
TFE (Figure 2B–D). Consistent with this, the NMR-derived struc-
ture of the closely related peptide uperin 3.6 is helical in 50%
aqueous TFE.[28] However, uperin 3.6 has no propensity to form
fibrils in aqueous solution or at any concentration of TFE (un-
published observations). From these data, it can be concluded
that the degree of a-helical structure present in the uperin 3.5
peptide precursor, which depends on the concentration of TFE,
plays a role in the peptide’s fibril formation. Low concentra-
tions of TFE, which introduce limited, dynamic helical structure,
result in enhanced fibril kinetics and yield, whereas at higher
concentrations of TFE, at which the peptide is trapped in a heli-
cal state, fibril formation does not proceed. Similar effects of
low amounts of TFE on fibril formation have been observed for
many other peptides and proteins. For example, we observed
such behaviour for eye-lens crystallin proteins in 10% TFE at
pH 2.0.[29] Given that uperin 3.5 adopts a predominantly a-heli-
cal structure in the presence of the membrane mimetic TFE, it
is likely that the membrane environment plays a role in the ag-
gregation of uperin 3.5.
Recently, IM-MS was used to investigate the self-assembly
processes of numerous amyloidogenic proteins and peptides.
The technique is ideally suited to this endeavour as it possible
to characterise heterogeneous populations with relative ease,
unlike many other commonly used biophysical methods.[18–19,30]
The mass spectrum shown in Figure 3A indicates that oligo-
meric species of uperin 3.5 from monomer to hexamer can be
observed under the conditions used.
Calibrated CCS values were plotted as a function of oligomer
number to give insight into the self-assembly process of the
oligomers (Figure 3D). From these data, it is possible to deter-
mine whether the self-assembly proceeds by a highly direc-
tional fibrillar process whereby the relationship between CCS
and oligomer number exhibits a linear correlation,[20] in con-
trast to the CCSs that would be expected for a spatially iso-
tropic self-assembly or a globular structure with a typical den-
sity. It is apparent for the small number of oligomers observed
that a linear regression line can be fitted to the CCS data (Fig-
ure 3D), that is, these data do not agree with the expected
CCS values for isotropic and spherical assemblies. It is conclud-
ed that a highly directional, fibrillar type self-assembly process
predominates for uperin 3.5 in the early stages of its aggrega-
tion. Similarly, elongated, rather than globular, oligomers were
also observed by IM-MS for the type II diabetes-associated
peptide amylin[19a] and for b2-microglobulin, the protein associ-
ated with dialysis-related amyloidosis.[31] Conversely, a study of
amyloid-b(1–42) oligomerisation by IM-MS led to a self-assem-
bly model with more complex architectures, notably ring-like
hexamers and a higher-order assembly comprising two stacked
hexameric units.[32]
For disease-related fibril-forming peptides and proteins,
there is a correlation between the induction of cytotoxicity
and the formation of the fibrillar state that is proposed to be
due to the presence of prefibrillar aggregates,[5a,8a, c, e–g,33] or, in
some instances, the fibrils themselves.[10a,13a, 21,24c] Conversely,
the non-aggregated forms of the protein have limited cytotox-
icity. Here, both the native and fibrillar species of uperin 3.5
caused a concentration-dependent decrease in PC12 cell viabil-
ity (measured by MTT reduction; Figure 4); however, the effect
of fibrillar uperin 3.5 was significantly enhanced at lower con-
Figure 5. EGCG inhibits amyloid-like fibril formation by uperin 3.5. A) In situ
ThT fluorescence assay of fibril formation by uperin 3.5 (*) and in the pres-
ence of EGCG (&). Addition of EGCG after the elongation phase (~) results in
a decrease in ThT fluorescence. Representative data are shown from three
independent experiments performed in triplicate. TEM images of the species
produced when uperin 3.5 was B) incubated for 24 h at 37 8C in PBS, C) incu-
bated in the presence of EGCG and D) incubated, followed by the addition
of EGCG after the elongation phase. Scale bars : 500 nm. E) MTT cytotoxicity
assay of PC12 cells treated with 1 mm uperin 3.5 preincubated at 37 8C for
24 h in RPMI 1640 medium in the presence and absence of EGCG. Treatment
with EGCG alone did not affect cytotoxicity. Values are presented as percent-
age of cell survival compared with a controlSEM of three independent ex-
periments, each with six replicates (* indicates P<0.05).
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centrations compared with that of the native peptide. For ex-
ample, at 0.5 mm, fibrillar uperin 3.5 reduced cell viability to
435%, compared with 923% for the native peptide. It has
been previously demonstrated that the integral nature of fibril-
lar species is maintained in cell culture media, and that fibril
formation still proceeds, albeit at a reduced rate.[10a] The effect
on cell viability of native uperin 3.5 at high concentrations
most probably arises from the formation of fibrillar species in
the culture medium, due to the high aggregation propensity
of uperin 3.5, which lacks a lag phase.[10a]
Flavonoids, such as EGCG from green tea, inhibit fibrillogen-
esis by amyloid-forming proteins both in vitro and in vivo. In
particular, EGCG inhibits fibril formation by numerous disease-
and non-disease-related amyloid-fibril-forming proteins such as
amyloid-b, a-synuclein and huntingtin, amongst others.[10c,
d,19a, 24c,34] The mechanisms by which EGCG and other flavonoids
achieve this are not well understood, and it is proposed that
many different types of intermolecular contacts might mediate
this inhibition.[35]
It is evident from the results presented herein that EGCG has
a similar effect in preventing aggregation by uperin 3.5. When
uperin 3.5 was incubated in the presence of four molar equiva-
lents of EGCG, there was a significant reduction in the maxi-
mum ThT fluorescence observed (Figure 5). These results were
confirmed by TEM analysis to determine the effects on mor-
phology. It is evident that co-incubation with EGCG results in
the formation of compact spherical oligomers, as opposed to
the fibrillar species observed in the absence of EGCG (Fig-
ure 5B–D).
In addition, EGCG has the ability to disaggregate and re-
model the amyloid fibrils formed by a number of disease-relat-
ed proteins.[36] The data obtained here show that EGCG remod-
els uperin 3.5, that the structures produced are not amyloid fi-
brils, and that they closely represent the structures produced
when EGCG is added at the start of the aggregation process
(Figure 5A).
Finally, it was demonstrated that coincubation of uperin 3.5
with EGCG prevents the decrease in cell viability in PC12 cells
that is associated with the amyloidogenic uperin 3.5 species
(Figure 5E). It should be noted that EGCG and other polyphe-
nols have properties that might also contribute to the preven-
tion of uperin 3.5 toxicity. These include their ability to scav-
enge radicals, reduce reactive oxidative species and to chelate
metal ions.[35a, 37] However, many other fibril-forming proteins
that give rise to similar morphologies upon EGCG treatment
have been studied, and in all instances, the soluble spherical
aggregates that are formed have been described as non-cyto-
toxic.[10c,d,19a, 24c,34]
Relevance of amyloid fibril formation to the AMP activity of
uperin 3.5
Much work in the area of AMPs is focussed on determining
their structures and modes of action as a means of implement-
ing and improving peptide antibiotics as therapeutics. It has
been proposed that the amyloidogenic nature of some AMPs,
namely the temporins B and L, means that soluble peptide
oligomers might be responsible for their antimicrobial activity,
and that the membrane might mediate amyloid formation. In
other words, there is an association between the toxic function
of the AMP and its ability to aggregate.[6] Consequently, there
could be a common mechanism of action of AMPs that have
the propensity to form amyloid fibrils.
Interestingly, it has been proposed that the oligomers
formed by amyloidogenic AMPs in a membrane might have
a mechanism of membrane permeabilisation different from
both the canonical barrel-stave and toroidal pore mechanisms.
This mechanism is termed the “leaky slit” model, and is based
on the formation of toxic oligomers in the bilayer.[13a, 15a,38] This
results in the formation of transmembrane linear, amphipathic
arrays of peptides that arrange with the hydrophobic faces in-
teracting with the bilayer. Consequently, the hydrophilic face
forces the lipids on this side to adopt a curved structure that
joins the inner and outer leaflets of the membrane, resulting in
membrane disruption.
Torrent et al.[6b] have observed that the amino acid sequen-
ces of aggregation-prone peptides and AMPs are closely corre-
lated at the amino acid level in their individual aggregation
propensity and antimicrobial index. Furthermore, the conver-
sion from aggregation-prone peptides to AMPs can be accom-
plished by the strategic insertion of positively charged lysine
or arginine amino acids into the peptide sequence to facilitate
binding to the negatively charged phospholipids of the bacte-
rial cell membrane. Intriguingly, of all the groups of organisms
studied, frog-skin AMPs have the greatest aggregation tenden-
cy. &&Torrent’s group’s OK?&& data imply that AMPs
evolved from aggregation-prone peptides through the selec-
tive incorporation of positively charged amino acids.
The apparent functional and evolutionary link between the
fibril formation of AMPs, such as uperin 3.5, and their mecha-
nism of antimicrobial action requires further research. It is con-
ceivable that research of this nature will provide significant in-
sights into the mechanism of disease-related amyloid cytotox-
icity.[15]
Conclusion
Many AMPs have the inherent ability to form amyloid struc-
tures. In this work, the amyloidogenicity of uperin 3.5 was in-
vestigated, and its ability to form amyloid fibrils was compared
with that of other disease-related proteins and peptides. It is
apparent that uperin 3.5 formed amyloid fibrils with rapid ki-
netics, as the process lacks a lag phase. The resultant fibrils
were of a typical coiled-coil ultrastructure, which is rich in b-
sheet content. Addition of the secondary-structure-inducing
cosolvent TFE enhanced fibril formation kinetics when small
quantities were present, but inhibited them at higher concen-
trations. The flexible a-helical structure induced at low TFE
concentrations can readily convert to b-sheet-rich amyloid.
However, at higher concentrations, the more rigid, well-defined
a-helical secondary structure is unable to convert. Fibrillar spe-
cies of uperin 3.5 were cytotoxic to cultured neuronal cells, in
a similar fashion to other disease-related amyloid species. This
supports the notion that the generic amyloid structure is toxic,
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and that the effect is sequence independent. Furthermore,
EGCG, a flavonoid from green tea, inhibited uperin 3.5 fibril
formation, remodelled the mature fibrils and prevented the cy-
totoxicity associated with uperin 3.5 fibril formation.
These data provide significant evidence for the structural
similarities between amyloid fibrils formed by uperin 3.5 and
those of disease-related proteins. Additionally, they provide
further support for the notion that fibrils formed by AMPs pos-
sess properties similar to those of disease-related amyloido-
genic proteins. Our work adds to the growing body of litera-
ture that suggests that mechanistic investigations of AMPs
that form amyloid structures can provide significant insight
into the means by which disease-related amyloid species elicit
their sometimes devastating effects.
Experimental Section
Materials: Unless otherwise stated, reagents were purchased from
Sigma–Aldrich. Peptides were synthesized by GenScript Corp. (Pis-
cataway, NJ, USA) or GenicBio (Shanghia, China) from l-amino
acids by using solid-phase methods and were greater than 80%
pure, respectively, as determined by HPLC and ESI-MS (Supporting
Information).
In-situ thioflavin T fluorescence assays: Samples for the in-situ
ThT assay were prepared by diluting concentrated peptide stock
solutions (typically 1 mm in H2O for uperin 3.5) into phosphate-buf-
fered saline (PBS, pH 7.4) solution at the appropriate concentra-
tions (100 mm uperin 3.5). The final concentration of ThT in the
samples was 10 mm. Samples were incubated at 37 8C in black
mClear 96-microwell plates (Greiner Bio-One, Stonehouse, UK) that
were sealed with clear film (Sigma–Aldrich) to prevent evaporation.
The ThT fluorescence intensities of the samples were recorded on
a Fluostar Optima plate reader (BMG Labtech, Offenburg, Germany)
fitted with 440/490 nm excitation/emission filters. Data were nor-
malized by plotting the relative change in ThT fluorescence [arbi-
trary units] between the initial and final fluorescence readings.
Transmission electron microscopy: Aliquots (5 mL) were taken
from samples after the ThT fluorescence assay and applied to the
surface of carbon-coated 400-mesh nickel TEM grids (ProSciTech,
Townsville, Australia). The grids were washed with milliQ H2O (3
10 mL) and negatively stained with uranyl acetate solution (2% w/v,
10 mL). Samples were viewed by using a Philips CM100 transmis-
sion electron microscope (Philips) or a Tecnai G2 Spirit transmission
electron microscope (FEI Company, Hillsboro, OR, USA).
Atomic force microscopy: AC-mode AFM images were obtained
by using a Nanowizard III AFM (JPK Instruments AG, Berlin, Germa-
ny) installed on a Nikon TE-2000 inverted epifluorescence micro-
scope. Cantilevers used were Bruker NCHV model, with a nominal
resonant frequency and spring constant of 320 kHz and 42 Nm1,
respectively. Line rates of 1–3 Hz were used, and images were pro-
cessed by using the JPK instrumental software. Samples for AFM
were placed as solution onto freshly-cleaved mica discs and dried;
imaging was performed in air.
Circular dichroism spectroscopy: Far-UV CD spectra were record-
ed on a J-815 CD spectropolarimeter (Jasco, MD, USA) by using
a 0.1 cm path-length cuvette and averaging of five scans. The
buffer contribution was subtracted for each experiment. Spectra
were recorded at 25 8C.
Ion mobility-mass spectrometry: Uperin 3.5 (100 mm) was dis-
solved in NH4OAc (20 mm). IM-MS spectra were acquired on
a Synapt HDMS system (Waters)[39] by using nanoelectrospray ioni-
sation (nanoESI) in positive-ion mode. The sample was introduced
by using platinum-coated borosilicate capillary needles that were
prepared in-house. Instrument parameters were optimised to
remove adducts whilst preserving noncovalent interactions, and
were typically as follows: capillary voltage: 1.7 kV, cone voltage:
100 V, trap collision energy: 10 V, source temperature: 50 8C, back-
ing pressure: 3.5 mbar, IMS cell pressure (N2): 0.5 mbar, travelling
wave velocity: &&300 ms1 OK?&&, travelling wave height: 8–
10 V. Drift-time measurements obtained from the Synapt HDMS
were normalised for charge state and calibrated to give a rotation-
ally averaged collision cross-section (CCS) according to a described
procedure.[22]
Cell culture: PC12 cells were cultured in RPMI 1640 medium (Invi-
trogen) supplemented with 5% (v/v) foetal bovine serum, l-gluta-
mine (2 mm), antibiotic/antimicotic mixture (100 mgmL1 penicillin
and 100 unitsmL1 streptomycin) and nonessential amino acids
(100 unitsmL1). Cells were grown in uncoated &&75 cm2 “cm3”?
&& plastic flasks at 37 8C in a 5% CO2-humidified incubator, and
subcultured every 3–7 days.
MTT assay: Cells were seeded the day prior to treatment at a densi-
ty of 2104 cells per well in a 96-well plate. Peptides (500 mm)
were dissolved in PBS and either snap-frozen on dry ice and stored
at 80 8C (nonfibrillar) or incubated at 37 8C for 24 h. The samples
were diluted in PBS to the required concentrations (10 mL) and
added to full-serum RPMI 1640 (100 mL). After a treatment time of
72 h, the culture medium was removed, and the cells were incu-
bated with serum-free medium containing methylthiazolyldiphen-
yl-tetrazolium bromide (0.25 mgmL1) for 3 h. The medium was re-
moved and replaced with dimethyl sulfoxide (100 mL), and the ab-
sorbance of the resultant formazan solution was measured at
560 nm by using a BMG Polarstar microplate reader (BMG Labtech).
Cell viability was assessed as percentage absorbance relative to
the vehicle control (PBS only) as the mean of three independent
experiments (six replicates per experiment). Where appropriate, dif-
ferences between data sets were evaluated by performing analysis
of variance (ANOVA) followed by Dunnett’s test. A level of p<0.05
was considered to be significant.
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The Amyloid-Fibril-Forming Properties
of the Amphibian Antimicrobial
Peptide Uperin 3.5
Frog-spawned fibrils: In solution, the
AMP uperin 3.5 rapidly forms amyloid fi-
brils that are toxic to model neuronal
cells. Mechanistically, the fibrils proceed
via an a-helical intermediate and can be
inhibited by the polyphenol EGCG. Sev-
eral oligomeric states have been identi-
fied by ion-mobility MS in solution. A
link between amyloid formation and
AMP activity is mooted.
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